Shares of Chiasma Inc. (NASDAQ:CHMA) rose 2.5% on Thursday . The stock traded as high as $2.87 and last traded at $2.82, with a volume of 78,734 shares traded. The stock had previously closed at $2.75.

Several equities analysts have recently commented on CHMA shares. Barclays PLC reaffirmed a “buy” rating and set a $40.00 price objective on shares of Chiasma in a research note on Thursday, March 31st. Cowen and Company reaffirmed a “hold” rating on shares of Chiasma in a research note on Friday, May 13th. Zacks Investment Research raised shares of Chiasma from a “sell” rating to a “hold” rating in a research note on Tuesday, April 19th. William Blair downgraded shares of Chiasma from an “outperform” rating to a “market perform” rating in a research note on Monday, April 18th. Finally, Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and set a $9.00 price objective (down from $43.00) on shares of Chiasma in a research note on Monday, April 18th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company’s stock. Chiasma currently has an average rating of “Hold” and an average target price of $19.70.

The stock’s 50-day moving average is $2.91 and its 200 day moving average is $7.46. The company’s market cap is $68.29 million.

Chiasma (NASDAQ:CHMA) last posted its earnings results on Wednesday, May 11th. The company reported ($0.71) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.63) by $0.08. On average, equities analysts forecast that Chiasma Inc. will post ($2.66) EPS for the current fiscal year.

Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.